July 3, 2024

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Recurrent cervical cancer is a life-threatening disease, with limited treatment options available when disease progression occurs after first-line combination therapy.

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Vergote et al. (Wed,) studied this question.

synapsesocial.com/papers/68e616d2b6db6435875a9dab https://doi.org/https://doi.org/10.1056/nejmoa2313811

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFcchimeric protein targeting tissue factor2011 · 48 citations
2Tissue Factor in Coagulation2009 · 177 citations
3Discrete sequential boundaries for clinical trials1983 · 1,741 citations
4New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)2008 · 29,583 citations
5Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor2011 · 42 citations

Demander à l'IA

Bookmark

View Full Paper